Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (41-50 of 204) with videos related to

Pageof 21
Sort By:
Communications Biology|June 3, 2021
Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapseGesham Magombedze, Jotam G Pasipanodya, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|August 26, 2017
pH Conditions under Which Pyrazinamide Works in HumansShashikant Srivastava, Jotam G Pasipanodya, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|December 19, 2025
Preclinical pharmacokinetics/pharmacodynamics studies defining the role of ethambutol in <i>Mycobacterium kansasii</i> lung diseaseTawanda Gumbo, Gunavanthi D Boorgula, Shashikant Srivastava
The Journal of Antimicrobial Chemotherapy|September 4, 2014
Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational studyJotam G Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|January 27, 2016
Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium DiseaseDevyani Deshpande, Jotam G Pasipanodya, Tawanda Gumbo
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 18, 2012
Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugsJotam G Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
The New England Journal of Medicine|February 5, 2015
Shorter moxifloxacin-based regimens for drug-sensitive tuberculosisJan-Willem Alffenaar, Tawanda Gumbo, Rob Aarnoutse
Antimicrobial Agents and Chemotherapy|May 25, 2016
Thioridazine as Chemotherapy for Mycobacterium avium Complex DiseasesDevyani Deshpande, Shashikant Srivastava, Sandirai Musuka, et al.
The Journal of Infectious Diseases|May 27, 2015
Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academiaTawanda Gumbo, Iñigo Angulo-Barturen, Santiago Ferrer-Bazaga
Antimicrobial Agents and Chemotherapy|September 22, 2025
Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of <i>Mycobacterium tuberculosis</i>Sanjay Singh, Megan Devine, Tawanda Gumbo, et al.
Pageof 21

Showing results (41-50 of 204) with videos related to

Sort By:
Pageof 21
Communications Biology|June 3, 2021
Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapseGesham Magombedze, Jotam G Pasipanodya, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|August 26, 2017
pH Conditions under Which Pyrazinamide Works in HumansShashikant Srivastava, Jotam G Pasipanodya, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|December 19, 2025
Preclinical pharmacokinetics/pharmacodynamics studies defining the role of ethambutol in <i>Mycobacterium kansasii</i> lung diseaseTawanda Gumbo, Gunavanthi D Boorgula, Shashikant Srivastava
The Journal of Antimicrobial Chemotherapy|September 4, 2014
Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational studyJotam G Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|January 27, 2016
Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium DiseaseDevyani Deshpande, Jotam G Pasipanodya, Tawanda Gumbo
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 18, 2012
Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugsJotam G Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
The New England Journal of Medicine|February 5, 2015
Shorter moxifloxacin-based regimens for drug-sensitive tuberculosisJan-Willem Alffenaar, Tawanda Gumbo, Rob Aarnoutse
Antimicrobial Agents and Chemotherapy|May 25, 2016
Thioridazine as Chemotherapy for Mycobacterium avium Complex DiseasesDevyani Deshpande, Shashikant Srivastava, Sandirai Musuka, et al.
The Journal of Infectious Diseases|May 27, 2015
Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academiaTawanda Gumbo, Iñigo Angulo-Barturen, Santiago Ferrer-Bazaga
Antimicrobial Agents and Chemotherapy|September 22, 2025
Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of <i>Mycobacterium tuberculosis</i>Sanjay Singh, Megan Devine, Tawanda Gumbo, et al.
Pageof 21